Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study ...Middle East

NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The Netherlands). The multicentric prospective...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study )

Also on site :

• Matthew Goode Explains Absence From ‘Downton Abbey 3’: “Maybe It’s A Good Thing”
• ‘America is not for sale:’ Protesters mob Trump golf course guests ahead of exclusive crypto dinner
• Spirit Halloween Issues Notice About 'Disruptions' Impacting Upcoming Season Opening